Skip to main content
Premium Trial:

Request an Annual Quote

Whatman Terminates S&S s IsoCode License as Part of Patent Infringement Settlement

NEW YORK, July 13 (GenomeWeb News) - Whatman said today that it has terminated a licensing deal with Schleicher & Schuell as part of a settlement agreement for a patent infringement lawsuit related to Whatman's FTA DNA isolation technology.


Whatman said it initiated the lawsuit in the United States in 2003 "to stop S&S exceeding the terms of the license that had been granted to S&S for the manufacture and sale of a product based on Whatman's FTA technology." Whatman said today that it has negotiated "the termination of the license altogether," and acquired some further patents related to S&S's DNA related technology.


Under the terms of the settlement, Whatman has terminated a license agreement under which S&S was selling its IsoCode DNA storage products and has acquired some patents related to S&S's IsoCode technology. S&S will continue to supply the IsoCode products "for a transitional period," to a "limited number" of existing customers," Whatman said.


Whatman said it will also pay S&S $500,000 under the settlement agreement.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.